Meet the Team
Kuan Chee Mun was previously responsible for Advanced Technology Development at Becton Dickinson & Co. (Asia-Pacific), a Fortune 500 medical device multinational company. He focused on identifying new business opportunities and developing product concepts & technologies to address unmet needs of customers from China, India and other Asia Pacific economies. Prior to this appointment, Chee Mun was the General Manager for the first international subsidiary of the Johns Hopkins University School of Medicine, based in Singapore. He began his career in academic research in molecular biology, and later joined the Singapore National Science & Technology Board.
Chee Mun holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Science (Honours) in Cell & Molecular Biology from the National University of Singapore.
Lawrence Lim was previously a Staff R&D Engineer at Becton Dickinson & Co. (Asia-Pacific) where he led teams in developing intravenous therapy medical devices. He brings a rich background in product development, having worked in cross-functional teams that took projects from product concept through to manufacturing and marketing. He practiced Design for Six Sigma (DFSS) methodologies in new product development and is a certified DFSS ‘Black Belt’. Lawrence holds 6 granted patents from his work in Becton Dickinson. He was formerly a Senior Mechanical Design Engineer at Delphi Automotive Systems.
Lawrence holds an MBA from the University of Strathclyde, MSc in Smart Product Design and Bachelor of Engineering (Honours) from the Nanyang Technology University.
Prior to joining AIM Biotech’s team, Lim Sei Hien was a member of Prof. Roger Kamm’s lab and focused on developing strategies for neovascularization that are of great interest to tissue repair and regeneration. He has a wealth of experience in establishing cell-based functional models in microfluidics for research applications.
Sei Hien received his Ph.D. in Bioengineering from the National University of Singapore with the support from the Singapore-MIT Alliance for Research and Technology (SMART) graduate fellowship.
Andrea Pavesi is a consultant to AIM Biotech and one of its founding team members. He is an entrepreneurial scientist with a Ph.D. in Biomedical and Biomechanical Engineering and 7 years of experience in the full spectrum of biomedical engineering and lab-on-a-chip technologies. A former Research Scientist at the Singapore-MIT Alliance for Research and Technology (SMART), he is currently a Junior Investigator at the Institute of Molecular and Cell Biology in Singapore. Andrea is also a graduate of the ESSEC Business School.
Scientific Advisory Board
Roger D. Kamm is the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT. He is the recipient of numerous awards including the ASME Lissner Award and the European Society of Biomechanics Huiskes Medal. He was elected to be a member of the National Academy of Medicine in 2010. A primary objective of Kamm’s research group is the application of fundamental concepts in fluid and solid mechanics to better understand essential biological and physiological phenomena. His lab focuses on the molecular mechanisms of cellular force sensation, and the development of new microfluidic technologies for vascularized engineered tissues and models of metastatic cancer. He is co-founder of two companies, CardioVascular Technologies, and AIM Biotech.
Seok (Sid) Chung is an Associate Professor in the School of Mechanical Engineering, Korea University. He is now a visiting professor in Mechanobiology laboratory at MIT for one year of 2015. He leads a research group working on hydrogel incorporating microfluidic cell culture assay and microscale tissue reconstitution. He obtained MS (1998) and PhD degree (2002) in School of Mechanical and Aerospace Engineering, Seoul National University. After five years building and working at a start-up company (NanoEntek Co. (KOSDAQ 039860)), he worked with professor Roger D. Kamm at MIT as post-doctoral fellow for four years. He joined Korea University as faculty member in 2009.
Prof Chwee Teck Lim is a Provost’s Chair Professor from the National University of Singapore. He is a biomedical engineer and his research interests include the development of microfluidic biochips for human disease detection and diagnosis. Prof Lim has authored more than 270 journal papers (including 40 invited/review articles), 26 book chapters and delivered more than 260 invited talks. He is also on the editorial boards of 14 journals and co-founded four startups. Prof Lim and his team have won more than 50 research awards and honors including the Vladimir K. Zworykin Award in 2015, Outstanding Researcher Award and Outstanding Innovator Award in 2014, the Credit Suisse Technopreneur of the Year Award, Wall Street Journal Asian Innovation Award (Gold) in 2012, TechVenture Rising Star Innovator Award and President's Technology Award in 2011 and the IES Prestigious Engineering Achievement Award in 2010 among others.
Jean Paul Thiery is currently CNRS emeritus scientist in Paris and a Visiting Professor at the National University of Singapore (NUS). He was until June 2015, Professor and Head of the Biochemistry Department, School of Medicine, NUS. He also had a joint appointment as Research Director at IMCB A*STAR Singapore and was Senior Principal Investigator at the Cancer Science Institute at NUS. In 2006, he moved to Singapore from his position as Head of Translational Research at the Medical Division of the Comprehensive Cancer Center of Institut Curie, and before that, Head of the Cell Biology Department at the Institut Curie in Paris until 2003. After his PhD studies at the University of Paris, his postdoctoral research with Gerald Edelman (Nobel Laureate) at the Rockefeller University led to the discovery of N-CAM, the first intercellular adhesion molecule to be identified. His influential works include pioneering studies in cell adhesion and migration in early embryogenesis and in elucidating the roles of growth factors and adhesion signaling molecules in Epithelial-Mesenchymal Transitions (EMT). Jean Paul Thiery’s current research focus is to unravel the mechanisms of invasion and metastasis of carcinoma cells. His seminal contributions to bladder carcinoma studies have led to the discovery of the molecular mechanisms underlying the formation of superficial or invasive tumors. Currently, his laboratory is focusing on oncogenomics and the creation of functional approaches to characterize breast and ovarian carcinoma with the ultimate goal to apply EMT-based therapeutic approaches. Jean Paul Thiery is an EMBO and Academia Europea member.
Board of Directors
Dr. Gertler is Co-founder, Managing Partner and CEO at Back Bay Life Science Advisors. He has been advising companies in the life sciences since the 1990s. Dr. Gertler provides counsel on franchise and therapeutic-area strategies, and corporate and business development activities. In addition, he advises clients on planning and is actively involved in the execution of value-creating transactions across the spectrum of company size and stage. His practice encompasses North American and European public and private commercial-stage and R&D-stage companies from mid to large cap, venture-backed companies, and investment firms focused on the life sciences. Prior to co-founding Back Bay, Dr. Gertler served as Senior Partner and Managing Director of Leerink Swann Strategic Advisors, the consulting arm of Leerink Swann. From 2001-2008, he also led several investment banking groups: BioPharma Investment Banking at Leerink Swann and Health Care Investment Banking at Adams Harkness/Canaccord Adams. In this capacity, he advised on a large number of equity, partnering and M&A transactions that total multi-billions in aggregate consideration.
From 1998 to 2001, during the latter stages of his full-time academic career, Dr. Gertler was also a Venture Partner for Schroder Ventures, now SV Life Sciences. He had active involvement in five of the Fund’s investments and continues to actively counsel and work with the venture community.
In addition to Back Bay, Dr. Gertler has founded three start-up companies: Antyllus Therapeutics, a current development-stage therapeutics company focused on new treatments for cardiovascular indications; Biofeedback Systems Design, a revenue-stage, software-based biofeedback company targeting the educational sector; and CardioVascular Technologies, an endovascular start-up based on one of his inventions in the area of embolic entrapment. In 2000, CardioVascular Technologies was acquired by Embolic Protection Inc., which was subsequently acquired in 2001 by Boston Scientific.
After training at Columbia University (MD), Yale New Haven Hospital (General Surgery) and the Massachusetts General Hospital (Vascular Surgery), Dr. Gertler was a practicing academic Vascular Surgeon, first as Chief of Vascular Surgery at SUNY-HSCB in New York from 1988 to 1992, and subsequently at the Massachusetts General Hospital (MGH) from 1992 to 2001. He was Associate Professor of Surgery at Harvard Medical School and Co-Director of the Vascular Research and Diagnostic Laboratories at the MGH.
Dr. Gertler has published extensively in clinical vascular surgery and endothelial and smooth muscle cell biology. He has served as an ad-hoc editor for, among others, the Journal of Vascular Surgery, The New England Journal of Medicine, The Journal of Critical Care Medicine, and Surgery, is a frequent lecturer and speaker on strategic issues facing life science companies at all stages and continues to publish in this regard. He currently serves on the Dean’s Advisory Board at Boston University School of Medicine and has previously been a member of a number of private and public companies and non-profit organizations. Along with an MD from Columbia University College of Physicians and Surgeons, Dr. Gertler has a BA from Wesleyan University and an MBA in Health Policy and Management from Boston University. He is a Fellow of the American College of Surgeons and a member of numerous academic and clinical surgical societies. Dr. Gertler is a Series 24 Registered Securities Principal. Jonathan is married with 3 grown sons, and is an avid musician, athlete, and fly fisherman